Skip to main content
. 2018 Apr 27;109(5):1532–1544. doi: 10.1111/cas.13585

Figure 4.

Figure 4

MicroRNA‐19a (miR‐19a) promotes gallbladder cancer (GBC) cell metastasis and stemness in vitro. A‐C, Cell migration and invasion assays were carried out in NOZ and GBC‐SD cells that were transfected with equal doses of mimic negative control (NC), miR‐19a mimic, inhibitor NC, or miR‐19a inhibitor. A, Representative images are shown. Scale = 100 μm. B, C, Quantitative analysis of the number of migrated and invaded cells. *P < .05; **P < .01. D, E, Wound‐healing assays were used to reveal the migration of treated NOZ cells. D, Representative images are shown. Scale = 100 μm. E, Quantitative analysis of wound closure. **P < .01; ***P < .001. F‐H, Immunoblotting analyses of the levels of epithelial–mesenchymal transition (EMT) marker proteins, cancer stem cell (CSC) marker protein, and PTEN in GBC cells after transfection with equal doses of mimic NC, miR‐19a mimic, inhibitor NC, or miR‐19a inhibitor. (F) Immunoblotting analyses of the levels of EMT marker proteins. E‐cad, E‐cadherin; N‐cad, N‐cadherin. G, Immunoblotting analyses of the levels of CSC marker proteins. H, Immunoblotting analyses of the levels of PTEN. I, Binding sites of miR‐19a in wild‐type (Wild) or mutant (Mut) PTEN 3ʹ‐UTRs. J, Relative luciferase activity of wild‐type or mutant PTEN 3ʹ‐UTR in GBC‐SD cells after transfection with miR‐19a mimic or mimic NC. **P < .01. ns, not significant